Henlius Gets Green Light For Adalimumab In China
Company Expands Biosimilars Portfolio With Its Third Monoclonal Antibody
After receiving approval from the Chinese regulatory body for rituximab and trastuzumab, Shanghai Henlius Biotech has now received approval for its HLX03 adalimumab biosimilar rival to Humira. The company has partnered with Wanbang Biopharma for commercialization of HLX03 in China.
